Plain-English translation of NCT06091475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
About one-third of people with heart failure experience remarkable recovery—their heart function returns to normal with medical treatment. This trial is testing whether people in this recovery phase can safely stop taking some of their heart medications, specifically spironolactone, eplerenone, dapagliflozin, and empagliflozin, while continuing others. The study will carefully monitor whether the heart stays healthy after stopping these treatments.
Doctors don't yet know which medications people truly need after their hearts have recovered. A previous study showed that stopping certain medications caused about 40% of patients to relapse, meaning their heart problems came back. This trial aims to figure out the minimum medications needed to keep people healthy long-term.
You will be randomly assigned to either stop your medications gradually over 4-16 weeks, or continue them for 16 weeks before stopping. Throughout the 8-month study, you'll have regular heart imaging scans (cardiovascular magnetic resonance) and blood tests to monitor your heart's response. Researchers will watch closely for any signs that your heart is struggling again, and will restart medications if needed.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United Kingdom